More than 70% of patients with metastatic breast cancer (MBC) present with hormone receptor‐positive disease.1 Endocrine therapy is the recommended initial treatment for hormone receptor‐positive metastatic disease in the current guidelines, even with visceral metastases.2 Prospective trials have shown that endocrine therapy, such as fulvestrant with or without a CDK 4/6 inhibitor, may substantially improve progression‐free survival (PFS) with good patient tolerance.3, 4, 5, 6. Here, NR4A1 is linked to metastatic neoplasm.